Ishita Drugs & Indus P/E Ratio
Current P/E Ratio
28.12
High Valuation
High - Growth expectations or overvalued
Ishita Drugs & Indus (ISHITADR) P/E ratio is 28.12 (High), EPS (TTM) ₹2.60, current price ₹73.10 on BSE — High - Growth expectations or overvalued. Read ISHITADR dividend history for the complete payout history and dividend yield track record.
Current Valuation Metrics
P/E Ratio
28.12
Current Price
₹73.10
EPS (TTM)
₹2.60
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
54.97
Sector Median
31.4
Sector Rank
#11 of 194
Sector Percentile
5.7%
ISHITADR P/E Ratio — Valuation Signal & Historical Context
Ishita Drugs & Indus P/E 28.12 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see ISHITADR stock price BSE.
- Stock appears overvalued with PE of 28.12, suggesting caution for new investments
- Trading at discount to sector average PE of 54.97
ISHITADR vs Healthcare Peers — P/E Ratio Comparison
Ishita Drugs & Indus P/E 28.12 vs Healthcare average 54.97, median 31.4 — range 2.86–950.0.
Sector Average
54.97
Sector Median
31.4
Lowest P/E
2.86
Highest P/E
950.0
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.65 | ₹29 | Low |
| Phaarmasia | PHRMASI | 3.84 | ₹68 | Low |
| JFL Life Sciences | JFLLIFE | 4.64 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.69 | ₹7,502 | Low |
| Shelter Pharma | SHELTER | 5.32 | ₹50 | Low |
| Mono Pharmacare | MONOPHARMA | 6.02 | ₹19 | Low |
| Royal Sense | ROYAL | 7.4 | ₹51 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹79 | Low |
| Amwill Health Care | AMWILL | 7.71 | ₹88 | Low |